Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute of Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Eur J Haematol. 2023 Jan;110(1):67-76. doi: 10.1111/ejh.13875. Epub 2022 Oct 17.
BACKGROUND: The SARS-COV-2 (Covid-19) pandemic has impacted the management of patients with hematologic disorders. In some entities, an increased risk for Covid-19 infections was reported, whereas others including chronic myeloid leukemia (CML) had a lower mortality. We have analyzed the prevalence of Covid-19 infections in patients with mastocytosis during the Covid-19 pandemic in comparison to data from CML patients and the general Austrian population. MATERIALS AND METHODS: The prevalence of infections and PCR-proven Covid-19 infections was analyzed in 92 patients with mastocytosis. As controls, we used 113 patients with CML and the expected prevalence of Covid-19 in the general Austrian population. RESULTS: In 25% of the patients with mastocytosis (23/92) signs and symptoms of infection, including fever (n = 11), dry cough (n = 10), sore throat (n = 12), pneumonia (n = 1), and dyspnea (n = 3) were recorded. Two (8.7%) of these symptomatic patients had a PCR-proven Covid-19 infection. Thus, the prevalence of Covid-19 infections in mastocytosis was 2.2%. The number of comorbidities, subtype of mastocytosis, regular exercise, smoking habits, age, or duration of disease at the time of interview did not differ significantly between patients with and without Covid-19 infections. In the CML cohort, 23.9% (27/113) of patients reported signs and symptoms of infection (fever, n = 8; dry cough, n = 17; sore throat, n = 11; dyspnea, n = 5). Six (22.2%) of the symptomatic patients had a PCR-proven Covid-19 infection. The prevalence of Covid-19 in all CML patients was 5.3%. The observed number of Covid-19 infections neither in mastocytosis nor in CML patients differed significantly from the expected number of Covid-19 infections in the Austrian population. CONCLUSIONS: Our data show no significant difference in the prevalence of Covid-19 infections among patients with mastocytosis, CML, and the general Austrian population and thus, in mastocytosis, the risk of a Covid-19 infection was not increased compared to the general population.
背景：SARS-COV-2（新冠病毒）大流行影响了血液系统疾病患者的管理。在某些实体中，报告了新冠病毒感染的风险增加，而其他实体（包括慢性髓性白血病[CML]）的死亡率较低。我们分析了在新冠病毒大流行期间肥大细胞增多症患者的新冠病毒感染患病率，并将其与 CML 患者和奥地利普通人群的数据进行了比较。
材料和方法：分析了 92 例肥大细胞增多症患者的感染和经 PCR 证实的新冠病毒感染的患病率。作为对照，我们使用了 113 例 CML 患者和奥地利普通人群中预期的新冠病毒感染患病率。
结果：在 25%的肥大细胞增多症患者（23/92）中，记录了感染的体征和症状，包括发热（n=11）、干咳（n=10）、咽痛（n=12）、肺炎（n=1）和呼吸困难（n=3）。其中 2 名（8.7%）有症状的患者经 PCR 证实感染了新冠病毒。因此，肥大细胞增多症患者的新冠病毒感染患病率为 2.2%。感染新冠病毒的患者与未感染的患者在合并症数量、肥大细胞增多症的亚型、定期运动、吸烟习惯、年龄或接受采访时的疾病持续时间方面无显著差异。在 CML 队列中，23.9%（27/113）的患者报告了感染的体征和症状（发热，n=8；干咳，n=17；咽痛，n=11；呼吸困难，n=5）。其中 6 名（22.2%）有症状的患者经 PCR 证实感染了新冠病毒。所有 CML 患者的新冠病毒感染患病率为 5.3%。在肥大细胞增多症和 CML 患者中观察到的新冠病毒感染数量与奥地利人群中预期的新冠病毒感染数量无显著差异。
结论：我们的数据显示，肥大细胞增多症、CML 和奥地利普通人群的新冠病毒感染患病率无显著差异，因此与普通人群相比，肥大细胞增多症患者感染新冠病毒的风险并未增加。
Curr Oncol Rep. 2022-5
Tohoku J Exp Med. 2022-9-6
Leukemia. 2020-5-18
J Cancer Res Clin Oncol. 2023-10
Ann Hematol. 2025-2
J Allergy Clin Immunol Glob. 2024-5-3
J Pers Med. 2022-11-10
Vaccines (Basel). 2022-5-4
Ann Allergy Asthma Immunol. 2022-6
J Allergy Clin Immunol Pract. 2022-5
Environ Sci Pollut Res Int. 2021-12
Cancer Epidemiol Biomarkers Prev. 2021-10
Zotero 插件
